Priavoid to Present Initial Phase 2 Safety Data for Alzheimer‘s and Preclinical PoC for Parkinson‘s Programs at AD/PDTM 2026

PUBLISHED Thursday, March 5, 2026 · priavoid gmbh

AI BRIEFING

⬤ Priavoid to present initial Phase 2 safety data for Alzheimer's and preclinical proof-of-concept for Parkinson's programs at AD/PDTM 2026.
⬤ Priavoid's lead candidate PRI-002 in Alzheimer's disease and PRI-101 in Parkinson's disease represent a novel class of orally available all-d-peptide therapeutics.
⬤ Priavoid's proprietary development platform is designed to detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders.